

Maturation and persistence of the anti-SARS-CoV-2 me

Cell

184, 1201-1213.e14

DOI: [10.1016/j.cell.2021.01.050](https://doi.org/10.1016/j.cell.2021.01.050)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
2	Will the large-scale vaccination succeed in containing the COVID-19 pandemic and how soon?. <i>Quantitative Biology</i> , 2021, 9, 304-316.	0.3	3
3	SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B cell responses. <i>Clinical and Translational Immunology</i> , 2021, 10, e1339.	1.7	11
5	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. <i>Microorganisms</i> , 2021, 9, 733.	1.6	22
7	Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> , 2021, 9, 556.	1.6	52
8	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
9	Coronavirus infection: An immunologists' perspective. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13043.	1.3	10
12	An examination of school reopening strategies during the SARS-CoV-2 pandemic. <i>PLoS ONE</i> , 2021, 16, e0251242.	1.1	16
14	Challenges and Issues of Anti-SARS-CoV-2 Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 664179.	1.2	16
17	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
19	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
20	Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection. <i>Antibody Therapeutics</i> , 2021, 4, 144-148.	1.2	6
21	Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. <i>Kidney International</i> , 2021, 99, 1275-1279.	2.6	60
22	Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. <i>BMC Medicine</i> , 2021, 19, 155.	2.3	34
24	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <i>Immunity</i> , 2021, 54, 1290-1303.e7.	6.6	101
26	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
29	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	13.5	73
33	Severe COVID-19 by SARS-CoV-2 Lineage B.1.1.7 in Vaccinated Solid-Organ Transplant Recipients: New Preventive Strategies Needed to Protect Immunocompromised Patients. <i>Vaccines</i> , 2021, 9, 806.	2.1	8

#	ARTICLE	IF	CITATIONS
34	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
36	Know your enemy or find your friend? Induction of IgA at mucosal surfaces. <i>Immunological Reviews</i> , 2021, 303, 83-102.	2.8	25
37	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	1.0	53
39	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230
40	The unique biology of germinal center B cells. <i>Immunity</i> , 2021, 54, 1652-1664.	6.6	84
41	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 1841-1852.e4.	6.6	114
43	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	1.6	24
44	High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. <i>Cell Reports</i> , 2021, 37, 109823.	2.9	73
46	Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3
47	Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. <i>Journal of Neurology</i> , 2022, 269, 1114-1120.	1.8	23
48	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021, 6, eabj2901.	5.6	67
49	Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. <i>Science</i> , 2021, 24, 103006.	1.9	23
50	Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2313-2324.	4.8	31
51	Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725606.	1.8	8
52	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
53	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 751584.	2.2	11
54	Overview of the neutralizing antibody and memory B cell response kinetics in SARS-CoV-2 convalescent and/or mRNA vaccinated individuals.. <i>Systems Biology and Physiology Reports</i> , 2021, 1, 1-5.	0.4	2
55	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12

#	ARTICLE	IF	CITATIONS
56	SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. <i>Journal of Clinical Immunology</i> , 2021, 41, 1709-1722.	2.0	68
57	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
60	T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. <i>Journal of Leukocyte Biology</i> , 2022, 111, 355-365.	1.5	25
61	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses “are we our own worst enemy?”. <i>Nature Reviews Immunology</i> , 2022, 22, 47-56.	10.6	118
62	Temporal dynamics of persistent germinal centers and memory B cell differentiation following respiratory virus infection. <i>Cell Reports</i> , 2021, 37, 109961.	2.9	28
63	m6A Regulator-Mediated Methylation Modification Patterns and Characteristics of Immunity in Blood Leukocytes of COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 774776.	2.2	17
64	SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	24
65	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
66	The adaptation of SARS-CoV-2 to humans. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210127.	0.8	4
67	Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110214.	2.9	19
68	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. <i>Nature Medicine</i> , 2022, 28, 496-503.	15.2	215
69	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
70	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. <i>Cell Reports</i> , 2022, 38, 110235.	2.9	35
71	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
72	Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees. <i>Journal of Infection</i> , 2022, 84, 579-613.	1.7	27
73	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. <i>Nature Communications</i> , 2022, 13, 153.	5.8	45
74	Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19 convalescent individuals. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1225-1241.	1.5	5
75	Multiple early factors anticipate post-acute COVID-19 sequelae. <i>Cell</i> , 2022, 185, 881-895.e20.	13.5	605

#	ARTICLE	IF	CITATIONS
77	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
78	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. <i>IScience</i> , 2022, 25, 103659.	1.9	16
80	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	2.9	29
81	SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. <i>Cell Reports</i> , 2022, 38, 110336.	2.9	41
82	Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 664-672.	1.9	14
83	Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2022, 42, 1287-1296.	1.9	36
84	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
85	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). <i>European Journal of Immunology</i> , 2021, 51, 2708-3145.	1.6	198
86	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. <i>EBioMedicine</i> , 2021, 74, 103748.	2.7	17
87	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
88	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 2022, 225, 947-956.	1.9	13
90	Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies. <i>PLoS Computational Biology</i> , 2021, 17, e1009675.	1.5	33
91	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. <i>Frontiers in Immunology</i> , 2022, 13, 835104.	2.2	28
94	A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 902-913.	3.0	7
95	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
96	Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19. <i>Viral Immunology</i> , 2022, 35, 259-272.	0.6	4
99	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 114.	7.1	17
100	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5

#	ARTICLE	IF	CITATIONS
101	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	6.6	42
102	Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine. <i>Clinical Immunology</i> , 2022, 237, 108963.	1.4	4
103	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. <i>Antiviral Research</i> , 2022, 201, 105297.	1.9	3
104	SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. <i>Transplantation Direct</i> , 2021, 7, e792.	0.8	8
105	Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	5
106	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. <i>PLoS ONE</i> , 2021, 16, e0261656.	1.1	16
107	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	3.9	20
108	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. <i>Cell Reports</i> , 2021, 37, 110169.	2.9	34
109	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e1-e9.	2.9	25
111	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. <i>Frontiers in Immunology</i> , 2022, 13, 844727.	2.2	2
112	Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. <i>Frontiers in Immunology</i> , 2022, 13, 856033.	2.2	5
113	Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	16
114	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
115	Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. <i>Antibodies</i> , 2022, 11, 35.	1.2	3
116	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. <i>Immunity</i> , 2022, 55, 945-964.	6.6	32
117	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
118	Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production. <i>Journal of Immunology Research</i> , 2022, 2022, 1-7.	0.9	4
119	Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	15

#	ARTICLE	IF	CITATIONS
121	The epigenetic regulation of the germinal center response. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2022, 1865, 194828.	0.9	3
122	Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. <i>Viruses</i> , 2022, 14, 1082.	1.5	20
123	High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
125	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
126	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
127	Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. <i>Immunological Reviews</i> , 2022, 310, 27-46.	2.8	137
128	COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins. <i>Cell Reports</i> , 2022, 40, 111022.	2.9	8
129	Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein. <i>Vaccines</i> , 2022, 10, 1060.	2.1	4
130	Early human B cell signatures of the primary antibody response to mRNA vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17
131	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
132	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11
134	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
135	Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. <i>Cell Reports</i> , 2022, 40, 111160.	2.9	9
136	A booster dose of Delta-Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
137	COVID-19 and plasma cells: Is there long-lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
139	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	3.2	3
140	SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination. <i>Viral Immunology</i> , 0, , .	0.6	5
141	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. <i>International Journal of Biological Sciences</i> , 2022, 18, 4629-4641.	2.6	24

#	ARTICLE	IF	CITATIONS
142	Induction of Cross-Reacting Antibodies Against the COVID-19 by BCG Vaccination in the Mouse Model. <i>Current Microbiology</i> , 2022, 79, .	1.0	2
143	Examination of Common Coronavirus Antibodies in SARS-CoV-2-Infected and Uninfected Participants in a Household Transmission Investigation. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	0
145	Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
146	IL-10 revisited in systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
147	Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing. <i>Emerging Microbes and Infections</i> , 2022, 11, 2007-2020.	3.0	7
148	Hypoxia and hypoxia-inducible factor signals regulate the development, metabolism, and function of B cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
149	SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. <i>Viruses</i> , 2022, 14, 1861.	1.5	4
150	Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
151	Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	32
152	Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
153	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
154	Reply to Focosi et al. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
155	What are the prospects for durable immune control?. <i>Infectious Diseases Now</i> , 2022, , .	0.7	0
157	The role of B cells in COVID-19 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
158	Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
159	Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1550.	2.1	4
160	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
161	Human anti-smallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and long-lasting germinal center imprinting. <i>Immunity</i> , 2022, 55, 1872-1890.e9.	6.6	17

#	ARTICLE	IF	CITATIONS
162	Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
163	SARS-CoV-2 infection and multi-organ system damage: a review. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	17
165	Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1 β associate with COVID-19 fatal outcome: A cross-sectional analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
166	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10374.	1.8	10
168	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
169	Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	0
171	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. <i>EBioMedicine</i> , 2022, 85, 104294.	2.7	11
172	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. <i>Cell Reports</i> , 2022, 41, 111496.	2.9	20
173	Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response. <i>Vaccines</i> , 2022, 10, 1839.	2.1	5
174	Functional antibodies exhibit light chain coherence. <i>Nature</i> , 2022, 611, 352-357.	13.7	35
175	Infant Antibody Repertoires during the First Two Years of Influenza Vaccination. <i>MBio</i> , 2022, 13, .	1.8	3
176	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
177	Sustained seropositivity up to 20.5 months after COVID-19. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
178	Landscape of infection enhancing antibodies in COVID-19 and healthy donors. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6033-6040.	1.9	5
179	Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	17
181	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. <i>JCI Insight</i> , 2022, 7, .	2.3	5
182	Antibodies as drugs—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1519, 153-166.	1.8	2
183	High activation levels maintained in receptor-binding domain-specific memory B cells in people with severe coronavirus disease 2019. <i>Immunology and Cell Biology</i> , 2023, 101, 142-155.	1.0	1

#	ARTICLE	IF	CITATIONS
184	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. <i>IScience</i> , 2023, 26, 105726.	1.9	9
185	Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clones. <i>JCI Insight</i> , 2023, 8, .	2.3	6
186	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
187	Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. <i>Science Immunology</i> , 2023, 8, .	5.6	89
188	The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. <i>Nature Reviews Immunology</i> , 2023, 23, 304-316.	10.6	56
189	Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. <i>Nature Immunology</i> , 2023, 24, 186-199.	7.0	26
190	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
191	Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response. <i>Communications Biology</i> , 2022, 5, .	2.0	5
194	Functional heterogeneity in the memory B-cell response. <i>Current Opinion in Immunology</i> , 2023, 80, 102281.	2.4	0
197	Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
198	A Rapid Method for Detection of Antigen-Specific B Cells. <i>Cells</i> , 2023, 12, 774.	1.8	2
199	Demultiplexing Ig repertoires by parallel mRNA/DNA sequencing shows major differential alterations in severe COVID-19. <i>IScience</i> , 2023, 26, 106260.	1.9	1
200	Complementarity determining regions in SARS-CoV-2 hybrid immunity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
201	Memory B-cell diversity: From early generation to tissue residency and reactivation. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	1
202	Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. <i>Nature Communications</i> , 2023, 14, .	5.8	6
203	Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination. <i>Viruses</i> , 2023, 15, 627.	1.5	2
205	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	15
206	Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients. <i>Immuno</i> , 2023, 3, 86-111.	0.6	1

#	ARTICLE	IF	CITATIONS
207	Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 627.	0.8	1
208	Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
209	Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. <i>Nature Communications</i> , 2023, 14, .	5.8	10
210	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
213	Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses. <i>Clinical and Experimental Immunology</i> , 0, , .	1.1	0
214	Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
229	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
240	Immune imprinting and next-generation coronavirus vaccines. <i>Nature Microbiology</i> , 2023, 8, 1971-1985.	5.9	4
241	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
252	B cell responses to SARS-CoV-2. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , .	0.9	0